| Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma M Attal, V Lauwers-Cances, C Hulin, X Leleu, D Caillot, M Escoffre, ... New England Journal of Medicine 376 (14), 1311-1320, 2017 | 1271 | 2017 |
| Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study P Moreau, H Pylypenko, S Grosicki, I Karamanesht, X Leleu, ... The lancet oncology 12 (5), 431-440, 2011 | 1191 | 2011 |
| TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis C Quivoron, L Couronné, V Della Valle, CK Lopez, I Plo, O Wagner-Ballon, ... Cancer cell 20 (1), 25-38, 2011 | 1014 | 2011 |
| Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA … P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ... The Lancet 394 (10192), 29-38, 2019 | 941 | 2019 |
| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 741 | 2020 |
| Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients K Belhadj, F Reyes, JP Farcet, H Tilly, C Bastard, R Angonin, E Deconinck, ... Blood 102 (13), 4261-4269, 2003 | 515 | 2003 |
| Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, ... Blood, The Journal of the American Society of Hematology 130 (8), 974-981, 2017 | 497 | 2017 |
| High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized … JP Fermand, S Katsahian, M Divine, V Leblond, F Dreyfus, M Macro, ... Journal of clinical oncology 23 (36), 9227-9233, 2005 | 463 | 2005 |
| Ide-cel or standard regimens in relapsed and refractory multiple myeloma P Rodriguez-Otero, S Ailawadhi, B Arnulf, K Patel, M Cavo, AK Nooka, ... New England Journal of Medicine 388 (11), 1002-1014, 2023 | 273 | 2023 |
| Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma B Arnulf, H Pylypenko, S Grosicki, I Karamanesht, X Leleu, ... Haematologica 97 (12), 1925, 2012 | 168 | 2012 |
| Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy–associated C3 glomerulopathy S Chauvet, V Frémeaux-Bacchi, F Petitprez, A Karras, L Daniel, S Burtey, ... Blood, The Journal of the American Society of Hematology 129 (11), 1437-1447, 2017 | 158 | 2017 |
| A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. O Hermine, I Allard, V Lévy, B Arnulf, A Gessain, A Bazarbachi The hematology journal: the official journal of the European Haematology …, 2002 | 157 | 2002 |
| Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results AM Lesokhin, MH Tomasson, B Arnulf, NJ Bahlis, H Miles Prince, ... Nature medicine 29 (9), 2259-2267, 2023 | 151 | 2023 |
| Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease C Cohen, B Royer, V Javaugue, R Szalat, K El Karoui, A Caulier, ... Kidney International 88 (5), 1135-1143, 2015 | 144 | 2015 |
| A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis M Roussel, G Merlini, S Chevret, B Arnulf, AM Stoppa, A Perrot, ... Blood, The Journal of the American Society of Hematology 135 (18), 1531-1540, 2020 | 132 | 2020 |
| Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4; 14): IFM 2010-02 trial results X Leleu, L Karlin, M Macro, C Hulin, L Garderet, M Roussel, B Arnulf, ... Blood, The Journal of the American Society of Hematology 125 (9), 1411-1417, 2015 | 132 | 2015 |
| Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma A Chari, J Martinez-Lopez, MV Mateos, J Bladé, L Benboubker, A Oriol, ... Blood, The Journal of the American Society of Hematology 134 (5), 421-431, 2019 | 128 | 2019 |
| Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell Y Lepelletier, S Lecourt, A Renand, B Arnulf, V Vanneaux, JP Fermand, ... Stem cells and development 19 (7), 1075-1079, 2010 | 127 | 2010 |
| Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy R Szalat, B Arnulf, L Karlin, M Rybojad, B Asli, M Malphettes, L Galicier, ... Blood, The Journal of the American Society of Hematology 118 (14), 3777-3784, 2011 | 109 | 2011 |
| Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies AD Cohen, S Parekh, BD Santomasso, J Gállego Pérez-Larraya, ... Blood cancer journal 12 (2), 32, 2022 | 108 | 2022 |
